Skip to main content
SpringerLink
Log in

What are the global response rates to Helicobacter pylori eradication therapy?

  • Chapter
Helicobactor pylori

  • 158 Accesses

Abstract

In this chapter we discuss a systematic review of the literature which was performed to answer the question of what the worldwide success rates of Helicobacter pylori eradication treatment are currently. The effect of resistance to antibiotics on treatment effectiveness, especially metronidazole and clarithromycin, was also assessed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fischbach LA, Goodman KJ, Feldman M, Aragaki C. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int J Epidemiol 2002; 31: 128–39.

    Article  PubMed  Google Scholar 

  2. Laheij RJF, Van Rossum LGM, Jansen JBMJ, Straatman H, Verbeek ALM. Evaluation of treatment regimens to cure Helicobacter pylori infection-a meta-analysis. Aliment Pharmacol Ther. 1999; 13: 857–64.

    Article  PubMed  CAS  Google Scholar 

  3. Greenland S. Meta-analysis. In: Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia, PA: Lippincott-Raven Publishers. 1998: 643–73.

    Google Scholar 

  4. Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy. A meta-analytical approach. Dig Dis Sci. 2000; 45: 68–76.

    Article  PubMed  CAS  Google Scholar 

  5. Houben MHMG, Van de Beek D, Hensen EF, de Craen AJM, Rauws EAJ, Tytgat GNJ. A systematic review of Helicohacter pylori eradication therapy–The impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther. 1999; 13: 1047–55.

    Article  PubMed  CAS  Google Scholar 

  6. Megraud F, Lehn N, Lind T et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial–the MACH2 study. Antimicrob Agents Chemother. 1999; 43: 2747–2752.

    PubMed  CAS  Google Scholar 

  7. Lahaie RG, Gaudreau C Helicobacter pylori antibiotic resistance: trends over time. Can J Gastroenterol. 2000; 14: 895–9.

    PubMed  CAS  Google Scholar 

  8. Lind T, Megraud F, Unge P et al. The MACH 2 study: role of omeprazole in eradication of Helicobacter pylori with one-week triple therapies. Gastroenterology. 1999; 116: 248–53.

    Article  PubMed  CAS  Google Scholar 

  9. Chiba N. Omeprazole and clarithromycin with and without metronidazole for the eradication of Helicobacter pylori. Am J Gastroenterol. 1996; 91: 2139–43.

    PubMed  CAS  Google Scholar 

  10. Goh KL, Peh SC, Paraskthi N et al. Omeprazole 40 mg o.m. combined with amoxycillin alone or with amoxycillin and metronidazole in the eradication of Helicobacter pylori. Am J Gastroenterol. 1994; 89: 1789–92.

    PubMed  CAS  Google Scholar 

  11. Koizumi W, Tanabe S, Hibi K et al. A prospective randomized study of amoxycillin and omprazole with and without metronidazole in the eradication treatment of Helicobacter pylori. J Gastroenterol Hepatol. 1998; 13: 301–4.

    Article  PubMed  CAS  Google Scholar 

  12. O’Riordan T, Mathai E, Tobin E, et al. Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate. Gut. 1990; 31: 999–1002.

    Article  PubMed  Google Scholar 

  13. Pilotto A, Di Mario F, Franceschi M, et al. Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. Aliment Pharmacol Ther. 1996; 10: 1021–27.

    Article  PubMed  CAS  Google Scholar 

  14. Saberi-Firoozi M, Massarrat S, Zare S, et al. Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized, controlled study. Am J Gastroenterol. 1995; 90: 1419–23.

    PubMed  CAS  Google Scholar 

  15. Sant S, Xia H, Daw M, Gilvarry J, Keane C. Antimicrobial therapy for Helicobacter pylori associated duodenal ulcer: A long term follow up study. V. Workshop Gastroduodenal Pathology and Helicobacter pylori. 1992; W2. 6.

    Google Scholar 

  16. Stack WA, Knifton A, Thirlwell D, et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Am J Gastroenterol. 1998; 93: 1909–13.

    Article  PubMed  CAS  Google Scholar 

  17. Tursi A, Cammarota M, Montalto A, et al. Evaluation of the efficacy and tolerability of four different therapeutic regimens for the Helicobacter pylori eradication. Panminerva Med. 1996; 38: 145–9.

    PubMed  CAS  Google Scholar 

  18. Wong BCY, Xiao SD, Hu FL et al. Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. Aliment Pharmacol Ther. 2000; 14: 217–224.

    Article  PubMed  CAS  Google Scholar 

  19. Gisbert JP, Gonzalez L, Calvet X, Roque M, Gabriel R, Pajares JM. Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week; a meta-analysis of efficacy. Aliment Pharmacol Ther. 2000; 14: 1141–50.

    Article  PubMed  CAS  Google Scholar 

  20. Van Oijen AH, Verbeek AL, Jansen JB, De Boer WA. Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate–or proton pump inhibitor-based trip therapies. Aliment Pharmacol Ther. 2000; 14: 991–9.

    Article  PubMed  Google Scholar 

  21. Unge P. What other regimens are under investigation to treat Helicobacter pylori Infection? Gastroenterology. 1997; 113: 5131–48.

    Article  Google Scholar 

  22. Gisbert JP, Gonzalez L, Calvet X, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2000; 14: 1319–28.

    Article  PubMed  CAS  Google Scholar 

  23. Wong BCY, Chang FY, Abid S et al. Triple therapy with clarithromycin, omeprazole and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. Aliment Pharmacol Ther. 2000; 14: 1529–35.

    Article  PubMed  CAS  Google Scholar 

  24. Wang WH, Wong BCY, Lam SK. Pooled analysis of Helicobacter pylori eradication regimes in Asia. J Gastroenterol. Hepatol. 2000; 15: 1007–17.

    Article  PubMed  CAS  Google Scholar 

  25. Liao CC, Lee CL, Lee HY, Wu CH, Chen TC. Efficacy of different therapies for Helicobacter pylori eradication: a 5-year experience in a single center. Gut. 2002; 51: September Supplement II, Abstract A47.

    Google Scholar 

  26. Calvet X, Garcia N, Lopez T, Gisbert JP, Gene E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxicillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther. 2000; 14: 603–9.

    Article  PubMed  CAS  Google Scholar 

  27. Vakil N, Schwartz HJ, Lanza FL, et al. A prospective, controlled, randomized trial of 3-, 7-, and 10-day rabeprazole-based triple therapy for H. pylori eradication in the USA. Gastroenterology. 2002;122:Abstract 551.

    Google Scholar 

  28. Bardhan KD, Bayerdorffer E, Veldhuyzen van Zanten SJO et al. The HOMER study: the effect of increasing the dose of metronidazole when given with omeprazole and to cure Helicobacter pylori infection. Helicobacter. 2000; 5: 196–201.

    Article  PubMed  CAS  Google Scholar 

  29. Huang JQ, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment Pharmacol Ther. 1999; 13: 719–29.

    Article  PubMed  CAS  Google Scholar 

  30. Gill HH, Desai HG, Mehta PR et al. Mono and dual therapy for Helicobacter pylori associated gastritis. JAPI. 1991; 39 (10): 743–5.

    PubMed  CAS  Google Scholar 

  31. Briand GG, Burford N. Bismuth compounds and preparations with biological or medicinal relevance. Chem Rev. 1999; 99: 2601–57.

    Article  PubMed  CAS  Google Scholar 

  32. De Boer WA. A novel therapeutic approach for Helicobacter pylori infection: the bismuth-based triple therapy monocapsule. Expert Opin Investig Drugs. 2001; 10: 1559–66.

    Article  PubMed  Google Scholar 

  33. Lahaie R, Farley A, Dallaire D et al. Bismuth-based quadruple therapy with bismuth subcitrate, metronidazole, tetracycline and omeprazole in the eradication of Helicobacter pylori. Can J Gastroenterol. 2001; 15: 581–5.

    PubMed  CAS  Google Scholar 

  34. Malfertheiner P, Megraud R, O’Morain C et al. and The European Helicobacter pylori study group (EHPSG). Current concepts in the management of Helicobacter pylori infection–The Maastricht 2–200 Consensus Report. Aliment Pharmacol Ther. 2002; 16: 167–80.

    Article  PubMed  CAS  Google Scholar 

  35. VA Coelho LG, Leon-Barua R, Quigley EMM and representatives of the Latin-American National Gastroenterological society. Latin-American consensus conference on Helicobacter pylori infection. Am J Gastroenterol. 2000; 95: 2688–91

    Google Scholar 

  36. Lam, SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the Management of Helicobacter pylori infection. J Gastroenterol and Hepatol. 1998; 13: 1–12.

    Article  CAS  Google Scholar 

  37. Hunt R.H, Fallone, C, Veldhuyzen van Zanten, SJO, Sherman P, Smaill F, Thomson ABR and the Canadian Helicobacter Study Group. Risks and benefits of Helicobacter pylori eradication: Current Status. Can J Gastroenterol. 2002; 16: 57–62.

    PubMed  Google Scholar 

  38. Vallve M, Vergara M, Gisbert JP, Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther. 2002; 16: 1149–56.

    Article  PubMed  CAS  Google Scholar 

  39. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenerol. 2001; 36: 690–700.

    Article  CAS  Google Scholar 

  40. Leung WK, Graham DY. Rescue therapy for Helicobacter pylori. Curr Treat Options Gastroenterol. 2002; 5: 133–8.

    Article  PubMed  Google Scholar 

  41. Gisbert JP, Pajares JM. Review article: Helicobacter pylori `rescue’ regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. 2002; 16: 1047–57.

    Article  PubMed  CAS  Google Scholar 

  42. Samaranayake LP, Johnson NW. Guidelines for the use of antimicrobial agents to minimize development of resistance. Int Dent J. 1999; 49: 189–95.

    Article  PubMed  CAS  Google Scholar 

  43. Meyers JM, Silliman NP, Wang W et al. Risk factors for Helicobacter pylori resistance in the United States: The surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann Intern Med. 2002; 136: S67.

    Article  Google Scholar 

  44. Queiroz DM, Dani R, Silva LD, et al. Factors associated with treatment failure of Helicobacter pylori infection in a developing country. J Clin Gastroenterol. 2002; 35: 315–20.

    Article  PubMed  CAS  Google Scholar 

  45. Dani R, Queiroz M, Dias MGM et al. Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer. Aliment Pharmacol Ther. 1999; 13: 1647–52.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. C. Nash
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Fischbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Veldhuyzen van Zanten
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Gastroenterology, McMaster University Medical Centre, 1200 Main Street West, L8N 3Z5, Hamilton, Ontario, Canada

    Richard H. Hunt (Professor of Medicine, Director) (Professor of Medicine, Director)

  2. Department of Gastroenterology and Hepatology, Academic Medical Centre, 9 Meibergdreef, 1105 AZ, Amsterdam, The Netherlands

    Guido N. J. Tytgat (Professor) (Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Nash, C., Fischbach, L., van Zanten, S.V. (2003). What are the global response rates to Helicobacter pylori eradication therapy?. In: Hunt, R.H., Tytgat, G.N.J. (eds) Helicobactor pylori. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-1763-2_34

Download citation

  • DOI: https://doi.org/10.1007/978-94-017-1763-2_34

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-5778-5

  • Online ISBN: 978-94-017-1763-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation